RxDoctor Payments Data

Christa O'Hana Nobleza, MD

Neurocritical Care · Memphis, TNNPI 1811127475

Payments from drug & device makers

$21,258in general payments, 2019–2025

Across 29 payments — averaging $733.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$20K
  • Irras USA, Inc.$588
  • UCB, Inc.$138
  • Ceribell, Inc.$108
  • AstraZeneca$42
  • Portola Pharmaceuticals, LLC$35
  • plus $97 from 4 others

What the payments were for

  • Speaking & faculty fees$58858%
  • Food & beverage$42042%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neurocritical care providers in Tennesseeto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$45,775
Medicare patients
120
Services billed
259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurocritical care in Memphis

Where these figures come from

Is this you, or does something look wrong? →